Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
about
Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendationsA Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injuryThe role of angiogenic factors in fibroid pathogenesis: potential implications for future therapyDynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.Recent Advances in Uterine Fibroid Etiology.Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression.Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroidProinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implicationsEndocytic deficiency induced by ITSN-1s knockdown alters the Smad2/3-Erk1/2 signaling balance downstream of Alk5An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advancesTransforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabineRetinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells.EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balanceGrowth factors as active participants in carcinogenesis: a perspective.Conditional knockout of CTGF affects corneal wound healing.Uterine fibroids: clinical manifestations and contemporary management.Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.Targeting TGF-β Signaling for Therapeutic Gain.Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition.Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin-mediated TGF-β activation.Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).Role of Transforming Growth Factor β in Uterine Fibroid Biology.Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.Proliferative and nonproliferative lesions of the rat and mouse urinary system.Downregulation of CITED2 contributes to TGFβ-mediated senescence of tendon-derived stem cells.Meeting report: Urinary Pathology; sixth Research Triangle Park Rodent Pathology Course.MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma.Leiomyoma cellulare in the broad ligament of the uterus.
P2860
Q24567733-8CEF991B-14E0-44A9-91F1-7B8A37C7F358Q27323906-8B9E1701-70B1-4FEB-925B-DEA66835DF82Q28486225-912C7B15-8702-4B63-A55F-B45FF680AB8AQ29040166-CE1EE229-9F23-478E-8E99-0759D144C781Q30541201-BEC37671-9804-4033-BA34-7F62B22B5507Q33852886-C70717B7-7D7A-4827-808F-97E1089304F2Q34363852-B948EC40-DD23-4153-8016-CDA2386B6DE5Q34617098-876C793D-42B6-4CB0-9CBA-AE3E5CB4840CQ34674982-83619984-71B2-4C87-88CC-1D0D8845C9CDQ35328276-014A32FD-E942-434D-9B54-CF3AF7128CDDQ35522530-52D368EB-A6B8-408A-83A3-100B3930DD18Q35577672-112A650D-5BD8-4870-ACE8-9DAF16B927FFQ36198889-1DC3A932-C3F5-4EAF-B101-2C717FCE4E04Q36429931-608B5E31-087B-40DB-B3DC-6B3121D74971Q37029528-C57D98E5-1540-4C33-870C-3864B1109F95Q37336034-0EEF715B-8F4F-44B3-89F3-4144B8D45C2CQ37676697-0512E16B-F57E-4D9A-A3ED-6BC5C71024B9Q37682622-470C421E-C464-4788-97E4-D585ECF3181AQ38211241-4522553C-670D-4255-9A3E-040DFCF62329Q38895037-AF36A15C-4F59-4B42-BF3D-1043DF2EBE60Q39155151-455B575B-FFAD-4555-9A08-87E7F44363EEQ40064172-685CC1EB-3942-41F0-8E35-EAEEB9FCD24BQ42142377-F3062041-3734-4A05-B1C6-3CBE62CF9F59Q42732702-5F5B65A2-B872-4E40-997D-4F92995BC189Q47096314-3BB4589A-DED3-49A9-871A-F9AD7E7BA9DEQ47217486-BB23A4CD-4B28-42C7-8C01-6667E0661CEDQ48636042-E3C3955C-518C-44E3-97CF-5319C8CE749FQ50954802-198C6B4E-38A0-4F9F-B5C1-64D421C607C0Q53330942-27BCE4A2-F5E9-4FFE-943F-38C45ECF693FQ54215201-D6552891-8FA2-4150-B332-7EBE20542A74Q55114088-258A8B5D-D7D0-4980-AB13-C2AC11C410A0
P2860
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
description
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Mai 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/05/15)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/05/15)
@nl
наукова стаття, опублікована в травні 2007
@uk
مقالة علمية (نشرت في 15-5-2007)
@ar
name
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@ast
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@en
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@nl
type
label
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@ast
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@en
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@nl
prefLabel
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@ast
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@en
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@nl
P2093
P3181
P1476
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
@en
P2093
Caprice Cadacio
Cheryl L. Walker
Jeffrey I. Everitt
Kendall S. Frazier
Leslie I. Gold
Mark Burgert
Melisa J. Portis
Nicholas J. Laping
P304
P3181
P356
10.1158/1078-0432.CCR-06-1811
P407
P577
2007-05-15T00:00:00Z